P/LP variants in BRCA2 was the most prevalent in both lung cancer patients and the controls, while only P/LP variants in BRCA1 and TP53 genes were found to be significantly associated with lung cancer risk, with odds ratios (ORs) ranging from 4‐fold (BRCA1: OR, 4.193; 95%CI, 1.382–10.768) to 29‐fold (TP53: OR, 29.281; 95%CI, 1.523–1705.506). Here, TP53 is linked to lung carcinoma.